

Dihydroergotamine mesylate nasal spray
Effective 09/01/2022

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029

Overview

Dihydroergotamine mesylate nasal spray is used for the treatment of acute migraine headaches with or without aura by activation of serotonin (5HT), noradrenaline, and dopamine receptors located on intracranial blood vessels resulting in vasoconstriction.

Coverage Guidelines

Authorization may be granted for members who are new to the plan and currently receiving treatment with dihydroergotamine nasal spray excluding when the product is obtained as samples or via manufacturer's patient assistance program

OR

Approval of dihydroergotamine mesylate nasal spray will be granted if the member meets all the following criteria and documentation has been provided:

- The member has a diagnosis of acute migraine headaches with or without aura
- The member is 18 years of age or older
- The member has had inadequate response, adverse reaction, or contraindication to intranasal sumatriptan
- The member has had inadequate response, adverse reaction, or contraindication to intranasal Zomig (zolmitriptan)
- The quantity being prescribed does not exceed 8 units (vials) per 30 days

Continuation of Therapy

Reauthorization will be granted if documentation is submitted indicating a positive response to therapy

Limitations

1. Initial approvals will be granted for 6 months
2. Reauthorizations will be granted for 1 year

References

1. Migranal (dihydroergotamine mesylate nasal spray) [package insert]. Bridgewater, NJ: Bausch Health US, LLC; 2019.
2. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. *Neurology* 2000; 54:1553.
3. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2000; 55:754.
4. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. *Headache* 2012; 52:114.
5. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. *Neurology* 1994; 44:447.
6. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. *Arch Neurol* 1996; 53:1285.

Review History

11/20/2019 – Reviewed at P&T

07/22/2020 – Reviewed at July P&T Mtg; updated criteria from Migranal to dihydroergotamine. Effective 10/01/2020.

07/20/2022 – Reviewed and Updated at July P&T Mtg; separated out MH vs. Comm/Exch criteria. No clinical changes. Effective 09/01/2022.

